Eli Lilly just put another number on the board that is going to get a lot of attention in obesity medicine: 29% average weight loss at Week 31 with a combination of tirzepatide and the selective amylin receptor agonist eloralintide. In the same Phase 1b study, tirzepatide 15 mg alone produced roughly 17.8% weight loss over the same period.

The comparis…